A Phase II Randomized, Placebo Controlled, Double-blind, 4 Arms Dose-ranging Study to Evaluate the Efficacy and Safety of SHR0302 Compared to Placebo in Patients With Moderate to Severe Active Ulcerative Colitis.
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 22 Oct 2018
At a glance
- Drugs SHR 0302 (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Sponsors Reistone Biopharma
- 22 Oct 2018 According to a Reistone Biopharma media release, the US FDA has approved the IND for phase II clinical trial to investigate the efficacy and safety of SHR-0302 in moderate to severe ulcerative colitis (UC).
- 25 Sep 2018 New trial record